Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
TMO$680.00-26.03(-3.69%)Thermo Fisher Scientific Announces Quarterly Dividend5:00:04 PM ETWPM$131.25-0.25(-0.19%)Wheaton Precious Metals Announces Third Quarter 2026 Results and Record Year-to-Date Production, Sales Volume, Revenue, Earnings and Cash Flow5:00:00 PM ETANTUPDATE 1-A&O Shearman's $1.1 billion AI plan builds on law firms' tech investments4:51:58 PM ETLRCX$193.30-27.98(-12.64%)BUZZ-Chip firm Lam Research rises after announcing $25 bln stock buyback4:50:28 PM ETNVDA$181.91-18.38(-9.18%)Stock Market Today, Nov. 5: Nvidia Slides on AI Chip Selloff as Election Uncertainty Weighs4:49:38 PM ETPTGX$135.26-8.19(-5.71%)Protagonist Therapeutics Q3 revenue surges on Takeda payments4:48:48 PM ETWFC$84.52-2.94(-3.36%)Wells Fargo & Company (WFC) Presents at BancAnalysts Association of Boston Conference 2026 Transcript4:45:03 PM ETTSLA$340.60-44.58(-11.57%)Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms4:43:33 PM ETBAC$49.83-1.81(-3.51%)MEDIA-BofA Rejigs Global Credit Trading Businesses To Boost Liquidity - Bloomberg News4:43:14 PM ETMNKD$3.65-0.29(-7.36%)MannKind Q3 revenue rises on royalty gains4:43:13 PM ETDIS$116.70-2.28(-1.92%)Disney employees use a town hall meeting to press management for details on a possible next round of layoffs4:42:35 PM ETMSFT$530.00-26.01(-4.68%)Microsoft Q3 Earnings: The Only Top AI Hyperscaler Generating Positive FCF (Rating Downgrade)4:42:33 PM ETNVDA$181.91-18.38(-9.18%)Thursday's Final Takeaways: Mortgage Rates Continue Decline, NVDA Chips to China4:34:31 PM ETNVDA$181.91-18.38(-9.18%)Nvidia Plunges 9% as AI Selloff Wipes Out $2.3 Trillion | Closing Bell4:32:42 PM ETKLAC$130.50-19.15(-12.80%)KLA Declares Regular Cash Dividend4:30:14 PM ETMU$668.08-127.38(-16.01%)Micron Announces Board of Directors Retirement4:30:06 PM ETMU$668.08-127.38(-16.01%)Micron Announces Board of Directors Retirement4:30:00 PM ETKO$95.60-0.28(-0.29%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$218.08-22.90(-9.50%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETNVDA$181.91-18.38(-9.18%)Nvidia's Huang is asked to brief Congress on reported Chinese spy relationship4:09:56 PM ETLRCX$193.30-27.98(-12.64%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$125.00-18.08(-12.64%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$181.91-18.38(-9.18%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$340.60-44.58(-11.57%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ET

COGT · NASDAQ

Cogent Biosciences, Inc.

$29.21 -2.25 (-7.15%)

Company overview

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$5.1B
Employees
205
Headquarters
Waltham, MA
Website
cogentbio.com
CEO
Andrew R. Robbins
Listed
March 29, 2018
P/E
-9.48
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$3.5M
Operating income
-$362M
EBITDA
-$362M
Net income
-$354M
EPS
-$3.08
Total assets
$903M
Total debt
$239M
Earnings yield
-10.54%

Price chart

27.1131.3435.5639.7944.02
COGT 1D NASDAQ O32.03H32.03L29.94C31.49+0.43 (+1.38%)Vol2.23M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
COGTCogent Biosciences, Inc. Stock news Cogent Biosciences Q3 net loss widens on higher expenses Reuters
COGTCogent Biosciences, Inc. Stock news BRIEF-Cogent Biosciences Q3 Income From Operations USD -117.184 Million Reuters
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results GlobeNewswire
COGTCogent Biosciences, Inc. Press release Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference GlobeNewswire
COGTCogent Biosciences, Inc. Stock news Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Has Consensus Price Target of $51.56 Defense World
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) GlobeNewswire
COGTCogent Biosciences, Inc. Stock news Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat Seeking Alpha
COGTCogent Biosciences, Inc. Stock news Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks Investment Research
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results GlobeNewswire
COGTCogent Biosciences, Inc. Stock news Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST GlobeNewswire
COGTCogent Biosciences, Inc. Stock news Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares Fool - Investing News
COGTCogent Biosciences, Inc. Stock news This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million Fool - Investing News
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress GlobeNewswire
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results GlobeNewswire
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 GlobeNewswire
COGTCogent Biosciences, Inc. Stock news Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' Seeking Alpha
COGTCogent Biosciences, Inc. Stock news Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP) Defense World
COGTCogent Biosciences, Inc. Press release Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) GlobeNewswire
See more
FAQ

Questions about Cogent Biosciences, Inc.

What does Cogent Biosciences, Inc. do?
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
What is COGT's market cap?
Cogent Biosciences, Inc. (COGT) is a listed stock with a live quote. The latest market cap on this page is $5.1B.
Where is Cogent Biosciences, Inc. headquartered?
Cogent Biosciences, Inc. is headquartered in Waltham, MA.
How do I get COGT news from the API?
Call GET /v1/news?tickers=COGT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does COGT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for COGT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the COGT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs